410 related articles for article (PubMed ID: 20450175)
1. Binding or bending: distinction of allosteric Abl kinase agonists from antagonists by an NMR-based conformational assay.
Jahnke W; Grotzfeld RM; Pellé X; Strauss A; Fendrich G; Cowan-Jacob SW; Cotesta S; Fabbro D; Furet P; Mestan J; Marzinzik AL
J Am Chem Soc; 2010 May; 132(20):7043-8. PubMed ID: 20450175
[TBL] [Abstract][Full Text] [Related]
2. Direct binding assay for the detection of type IV allosteric inhibitors of Abl.
Schneider R; Becker C; Simard JR; Getlik M; Bohlke N; Janning P; Rauh D
J Am Chem Soc; 2012 Jun; 134(22):9138-41. PubMed ID: 22612329
[TBL] [Abstract][Full Text] [Related]
3. Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors.
Simard JR; Getlik M; Grütter C; Pawar V; Wulfert S; Rabiller M; Rauh D
J Am Chem Soc; 2009 Sep; 131(37):13286-96. PubMed ID: 19572644
[TBL] [Abstract][Full Text] [Related]
4. Discovery of allosteric BCR-ABL inhibitors from phenotypic screen to clinical candidate.
Gray NS; Fabbro D
Methods Enzymol; 2014; 548():173-88. PubMed ID: 25399646
[TBL] [Abstract][Full Text] [Related]
5. Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site.
Fabbro D; Manley PW; Jahnke W; Liebetanz J; Szyttenholm A; Fendrich G; Strauss A; Zhang J; Gray NS; Adrian F; Warmuth M; Pelle X; Grotzfeld R; Berst F; Marzinzik A; Cowan-Jacob SW; Furet P; Mestan J
Biochim Biophys Acta; 2010 Mar; 1804(3):454-62. PubMed ID: 20152788
[TBL] [Abstract][Full Text] [Related]
6. Exploration of (S)-3-aminopyrrolidine as a potentially interesting scaffold for discovery of novel Abl and PI3K dual inhibitors.
Zhang C; Tan C; Zu X; Zhai X; Liu F; Chu B; Ma X; Chen Y; Gong P; Jiang Y
Eur J Med Chem; 2011 Apr; 46(4):1404-14. PubMed ID: 21295380
[TBL] [Abstract][Full Text] [Related]
7. Allosteric lariat peptide inhibitors of Abl kinase.
Bharathikumar VM; Barreto K; Decoteau JF; Geyer CR
Chembiochem; 2013 Nov; 14(16):2119-25. PubMed ID: 24030821
[TBL] [Abstract][Full Text] [Related]
8. Tyrosine kinase inhibition: Ligand binding and conformational change in c-Kit and c-Abl.
Healy EF; Johnson S; Hauser CR; King PJ
FEBS Lett; 2009 Sep; 583(17):2899-906. PubMed ID: 19660459
[TBL] [Abstract][Full Text] [Related]
9. Insight into the allosteric inhibition of Abl kinase.
Fallacara AL; Tintori C; Radi M; Schenone S; Botta M
J Chem Inf Model; 2014 May; 54(5):1325-38. PubMed ID: 24787133
[TBL] [Abstract][Full Text] [Related]
10. The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation.
Cowan-Jacob SW; Fendrich G; Manley PW; Jahnke W; Fabbro D; Liebetanz J; Meyer T
Structure; 2005 Jun; 13(6):861-71. PubMed ID: 15939018
[TBL] [Abstract][Full Text] [Related]
11. Crystal structure of the abl-SH3 domain complexed with a designed high-affinity peptide ligand: implications for SH3-ligand interactions.
Pisabarro MT; Serrano L; Wilmanns M
J Mol Biol; 1998 Aug; 281(3):513-21. PubMed ID: 9698566
[TBL] [Abstract][Full Text] [Related]
12. Allosteric interactions between the myristate- and ATP-site of the Abl kinase.
Iacob RE; Zhang J; Gray NS; Engen JR
PLoS One; 2011 Jan; 6(1):e15929. PubMed ID: 21264348
[TBL] [Abstract][Full Text] [Related]
13. Structural basis for the cytoskeletal association of Bcr-Abl/c-Abl.
Hantschel O; Wiesner S; Güttler T; Mackereth CD; Rix LL; Mikes Z; Dehne J; Görlich D; Sattler M; Superti-Furga G
Mol Cell; 2005 Aug; 19(4):461-73. PubMed ID: 16109371
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and docking study of 2-phenylaminopyrimidine Abl tyrosine kinase inhibitors.
Lü S; Luo Q; Hao X; Li X; Ji L; Zheng W; Wang F
Bioorg Med Chem Lett; 2011 Dec; 21(23):6964-8. PubMed ID: 22033461
[TBL] [Abstract][Full Text] [Related]
15. Crystal structure of the T315I mutant of AbI kinase.
Zhou T; Parillon L; Li F; Wang Y; Keats J; Lamore S; Xu Q; Shakespeare W; Dalgarno D; Zhu X
Chem Biol Drug Des; 2007 Sep; 70(3):171-81. PubMed ID: 17718712
[TBL] [Abstract][Full Text] [Related]
16. Characterization of compound 584, an Abl kinase inhibitor with lasting effects.
Puttini M; Redaelli S; Moretti L; Brussolo S; Gunby RH; Mologni L; Marchesi E; Cleris L; Donella-Deana A; Drueckes P; Sala E; Lucchini V; Kubbutat M; Formelli F; Zambon A; Scapozza L; Gambacorti-Passerini C
Haematologica; 2008 May; 93(5):653-61. PubMed ID: 18367480
[TBL] [Abstract][Full Text] [Related]
17. Discovery and characterization of a cell-permeable, small-molecule c-Abl kinase activator that binds to the myristoyl binding site.
Yang J; Campobasso N; Biju MP; Fisher K; Pan XQ; Cottom J; Galbraith S; Ho T; Zhang H; Hong X; Ward P; Hofmann G; Siegfried B; Zappacosta F; Washio Y; Cao P; Qu J; Bertrand S; Wang DY; Head MS; Li H; Moores S; Lai Z; Johanson K; Burton G; Erickson-Miller C; Simpson G; Tummino P; Copeland RA; Oliff A
Chem Biol; 2011 Feb; 18(2):177-86. PubMed ID: 21338916
[TBL] [Abstract][Full Text] [Related]
18. 3D-QSAR studies on c-Src kinase inhibitors and docking analyses of a potent dual kinase inhibitor of c-Src and c-Abl kinases.
Thaimattam R; Daga PR; Banerjee R; Iqbal J
Bioorg Med Chem; 2005 Aug; 13(15):4704-12. PubMed ID: 15914012
[TBL] [Abstract][Full Text] [Related]
19. Enhanced SH3/linker interaction overcomes Abl kinase activation by gatekeeper and myristic acid binding pocket mutations and increases sensitivity to small molecule inhibitors.
Panjarian S; Iacob RE; Chen S; Wales TE; Engen JR; Smithgall TE
J Biol Chem; 2013 Mar; 288(9):6116-29. PubMed ID: 23303187
[TBL] [Abstract][Full Text] [Related]
20. Rapid synthesis of Abelson tyrosine kinase inhibitors using click chemistry.
Kalesh KA; Liu K; Yao SQ
Org Biomol Chem; 2009 Dec; 7(24):5129-36. PubMed ID: 20024108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
